Respiratory syncytial virus and other vaccine-preventable infections in Multiple Myeloma. A population-based study on 8672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry
Sigrun Einarsdottir,
Ingigerdur Sverrisdottir,
Mariana Villegas-Scivetti,
Chris Day,
Ingemar Turesson,
Gunnar Juliusson,
Markus Hansson,
Gunnar Larfors,
Cecilie Hveding Blimark
Affiliations
Sigrun Einarsdottir
Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg
Ingigerdur Sverrisdottir
Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg, Sweden; Department of Medicine, University of Iceland, Reykjavik
Mariana Villegas-Scivetti
Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg
Chris Day
Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg
Ingemar Turesson
Skåne University Hospital, Malmö/Lund
Gunnar Juliusson
Skåne University Hospital, Malmö/Lund
Markus Hansson
Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg
Gunnar Larfors
Unit of Hematology, Department of Medical Sciences, Uppsala University, Uppsale
Cecilie Hveding Blimark
Department of Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Hematology and Coagulation, Sahlgrenska University hospital, Gothenburg
